Becker's Healthcare June 27, 2024
Ashleigh Hollowell

An inhalable drug treatment for chronic obstructive pulmonary disease received FDA-approval June 26, drugmaker Verona Pharma announced.

It is the first FDA-approved treatment for COPD in more than two decades, according to the release.

“[D]espite maintenance therapy, most patients report grappling with daily symptoms, including breathlessness and persistent coughing,” Michael Wells, MD, associate professor in the division of pulmonary, allergy, and critical care medicine at the University of Alabama Birmingham,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Related Articles:
STAT+: Don’t write off MDMA yet: How the FDA got on board with psychedelics
Where the future of Alzheimer's drugs is heading
STAT+: FDA rejects Rocket Pharmaceuticals’ gene therapy for ultra-rare condition, another setback for field
STAT+: Vape makers see Supreme Court ruling as a weapon in fighting FDA
Non-binding Guidance: FDA Regulatory & Enforcement Risks Relevant to Academic Medical Centers, Health Systems and Research Institutions

Share This Article